Objective To assess the clinical efficacy and safety of Shuxuetong in the treatment of cerebral infarction. Methods Randomized controlled trials (RCTs) were identified from MEDLINE (1996 to Feb. 2006), EMBASE (1984 to Dec. 2005), Cochrane Controlled Trials Register (Issue 4, 2005), Chinese Cochrane Centre Database, CBMdisc (1978 to Dec. 2005). We handsearched the related published and unpublished data and their references. All trials about Shuxuetong injection for cerebral infarction were included. Data were extracted and evaluated by two reviewers independently with designed extraction form. RevMan 4.2.8 software was used for data analysis. Results Eleven RCTs involving 1 122 patients were included. The results of meta-analysis were listed as follows: ① Total effective rate: Compared with Danshen, three studies showed that Shuxuetong were more effective with OR 4.01, 95%CI 2.00 to 8.04; ② Adverse effect: The number of adverse drug reaction was small and the symptoms were moderate; ③ Neurologic impairment score: Compared with safflower, one study showed that Shuxuetong had better improvement with WMD -2.60, 95%CI -3.23 to -1.97. Conclusions Shuxuetong may increase the total effective rate of cerebral infarction. More high quality trials are required.
目的:观察采用疏血通注射液联合ACEI/ARB治疗早期糖尿病肾病(DN)的疗效。方法:将78例2型DN患者随机分为对照组(ACEI/ARB)和治疗组(ACEI/ARB+疏血通注射液),疗程4周。比较两组治疗前和治疗后尿微量白蛋白(mAlb),Scr、BUN等指标的变化。结果:(1)治疗后治疗组和对照组尿白蛋白均显著下降(Plt;0.01,Plt;0.05),治疗组比对照组下降更为明显(Plt;0.05)。(2)治疗后两组血浆白蛋白均增加(Plt;0.01),治疗组与对照组治疗后比较无明显差异(Pgt;0.05)。(3)治疗后两组Scr、BUN、TC、TG和血钾均无明显变化。结论:联合应用疏血通注射液能有效减少早期DN患者的蛋白尿,改善肾功能。
目的:研究疏血通联合奥扎格雷钠治疗进展性脑梗死的临床疗效。方法: 将62例进展性脑梗死患者随机分为两组,对照组30例,治疗组32例。对照组静滴丹参40mL,1/d,羟乙基淀粉40氯化钠500mL,1/d,治疗组静滴疏血通6mL,1/d,奥扎格雷钠160mg,1/d,疗程均为14天。观察两组总有效率及治疗前后神经功能缺损评分、血液流变学、脑血管平均血流速度的改变。结果: 治疗组对进展性脑梗死的总有效率为93.8%,对照组为73.3%,两组相比有显著性差异(Plt;0. 05)。治疗组治疗前后神经功能缺损评分、血液流变学指标、脑血流量均有明显改善,差异有显著性,而对照组则不明显。结论: 疏血通与奥扎格雷钠联合治疗进展性脑梗死能起到协同作用,可有效改善进展性脑梗死患者脑部血液循环,减轻梗死后脑组织的缺血坏死风险,最大程度降低病残率,改善患者的预后,其疗效优于丹参与羟乙基淀粉40氯化钠,且安全性高,是治疗进展性脑梗塞较为理想的药物。